A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia | Leukemia
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia - Journal of Oncology Navigation & Survivorship
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial - The Lancet
vyxeos Clinical Pharmacology Drug Monograph
7+3 (daunorubicin) for AML | ChemoExperts
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study | Leukemia
PRINCIPLES OF ANTINEOPLASTIC THERAPY
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study | Haematologica
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Daunorubicin - Wikipedia
A Review of Liposomal Daunorubicin in the Treatment of Acute Leukemia - touchONCOLOGY
Fernand Bteich on Twitter: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review | HTML
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients - Annals of Oncology
Effect of Ara-C, daunorubicin, mitoxantrone and etoposide on the... | Download Scientific Diagram
IJMS | Free Full-Text | A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine | HTML
Primary AML cells and cell lines resistant to cytarabine, daunorubicin... | Download Scientific Diagram
Acute myeloid leukemia—Major progress over four decades and glimpses into the future - Kantarjian - 2016 - American Journal of Hematology - Wiley Online Library
Cancer Management Chapter 29: Acute leukemias
Daunorubicin/cytarabine - Wikipedia
Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | PLOS ONE
